In recent years, targeted therapy (inhibitors of EGFR, ALK or ROS1 for NSCLC and inhibitors of PARP or DLL3 for SCLC) and immunotherapy (pembrolizumab, nivolumab, durvalumab, etc.)have been incorporated as therapeutic strategies for NSCLC and SCLC [185,186,187]. Here, ALK is linked to non-small cell lung carcinoma.